阿托伐他汀防治急性缺血性脑卒中42例疗效评价

Evaluation on efficacy of atorvastatin in the prevention and treatment of 42 cases with acute ischemic stroke

目的观察阿托伐他汀防治急性缺血性脑卒中的临床疗效及安全性。方法随机将同期收治的84例急性缺血性脑卒中患者分为观察组和对照组各42例,对照组给予基础治疗及口服肠溶阿司匹林片,每天1次,每次剂量100 mg;观察组在常规治疗及口服肠溶阿司匹林片的同时,给予口服阿托伐他汀,每天1次,每次20 mg,两组均以1个月为1疗程。观察两组疗效及治疗前后血脂水平变化,记录患者在服药期间发生的不良反应,包括胃肠道反应、肝功能异常、口腔出血、脑出血、皮疹等。结果对照组总有效率为69.0%(29/42);观察组总有效率达88.1%(37/42),观察组总有效率明显高于对照组,两组患者治疗前后的血脂水平比较,观察组的TG、TC及LDL-C等指标改善幅度大于对照组(P<0.05),对照组的血脂水平改善程度不明显;观察组42例中急性脑梗死2例(4.8%),低于对照组的5例(11.9%)。结论阿托伐他汀在急性缺血性脑卒中的防治上具有疗效突出、安全性高等优点,并能够显著改善血脂水平,且不良反应发生率低,值得临床应用。

Objective To observe the clinical efficacy and safety of atorvastatin in the prevention and treatment of a- cute ischemic stroke. Methods Atotal of 84 cases of acute ischemic stroke admitted during the same period were ran- domly divided into the observation group and the control group, and each group had 42 cases. The patients in the con- trol group were treated with basic therapy and 100 mg oral enteric aspirin tablet each times, 1 times a day; The patients in the observation group were treated with basic therapy and oral enteric aspirin tablet, as well as 20 mg oral atorvas- tatin each times, 1 times a day, and a alonth was a course of treatment in the two groups. The efficacy and changes of blood lipid levels before and after the treatment in the two groups were observed, and the adverse reactions of patients during the treatment phase were recorded, including gastrointestinal reactions, unusual liver function, oral hemorrhage, cerebral hemorrhage, rash. Results The total effective rate of the control group was 69.0%（29/42）, while that of the 0b- servation group was 88.1%（37/42）, and tlhe total effective rate of the observation group was obviously higher than that of the control group. The comparison of blood lipid levels in the two groups between before and after the treatment showed that compared with the control group, the TG, TC and LDL-C levels in the observation group improved more obviouly （P〈0.05）, while the blood lipid levels in the cofitrol group improved less obviously; 2 cases （4.8%） were acute cerebral infarction among the 42 cases of the observation group, which was lower than that of the control group[5 cases（11.9%）]. Conclusion Atorvastatin has prominent curative effect, high security in the prevention and treatment of acute ischemie stroke, and can significantly improve the blood lipid levels, and has low incidence rate of adverse reactions, and it is worthy of clinical application.